Evidence map›Paper›PMID 38775927›Full record

Trial reportInfection2024

Systemic immune markers and infection risk in preterm infants fed human milk fortified with bovine colostrum or conventional fortifier, a secondary analysis of the FortiColos trial.

Ole Bæk, Tik Muk, Lise Aunsholt, Gitte Zachariasen, Per Torp Sangild, Duc Ninh Nguyen

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Infection, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03537365 (Bovine Colostrum to Fortify Human Milk for Preterm Infants A Randomized, Controlled Pilot Trial), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03537365 nacompletednot on this map

Bovine Colostrum to Fortify Human Milk for Preterm Infants A Randomized, Controlled Pilot Trial

TypeinterventionalSponsorPer Torp SangildRan2017 to 2022Enrolled252ConditionsGrowth, Necrotizing Enterocolitis, Late-Onset Sepsis, Feeding IntoleranceArmsBovine Colostrum (BC) / intervention group, FM85 / control group
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ole BækComparative Pediatrics and Nutrition, Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg, Denmark.
Tik MukComparative Pediatrics and Nutrition, Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg, Denmark.
Lise AunsholtDepartment of Neonatology, Rigshospitalet, Copenhagen, Denmark.
Gitte ZachariasenHans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark.
Per Torp SangildComparative Pediatrics and Nutrition, Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg, Denmark. pts@sund.ku.dk.
Duc Ninh NguyenComparative Pediatrics and Nutrition, Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg, Denmark. dnn@sund.ku.dk.

Funding

Innovationsfonden 6150-00004B
6 · The paper itself

Abstract

backgroundFor very preterm infants, human milk is often fortified with formula products based on processed bovine milk. Intact bovine colostrum (BC), rich in anti-inflammatory milk factors, is considered an alternative. We investigated if BC affects anti-inflammatory/T

methodsFor a secondary analysis of a multicenter, randomized controlled trial (NCT03537365), very preterm infants (26-31 weeks gestation, 23% small for gestational age, SGA) were randomized to receive BC (ColoDan, Biofiber, Denmark, n = 113) or conventional fortifier (PreNAN, Nestlé, Switzerland, n = 116). Infection was defined as antibiotic treatment for five or more consecutive days and 29 cytokines/chemokines were measured in plasma before and after start of fortification.

resultsIn general, infection risk after start of fortification was associated with low gestational age, SGA status and antibiotics use prior to fortification. Adjusted for confounders, infants fortified with BC showed more infection episodes (20 vs 12%, P < 0.05) and higher cumulative infection risk (hazard ratio, HR 1.9, P = 0.06), particularly for SGA infants (HR 3.6, P < 0.05). Additionally, BC-fortified infants had higher levels of T

conclusionInfants fortified with BC displayed a delayed shift from T

Indexed as

ColostrumCytokinesFood, FortifiedInfant, PrematureMilk, HumanAnimalsBiomarkersCattleFemaleHumansInfant, NewbornMaleBiomarkersCytokinesAnti-inflammatoryBovine colostrumFortificationImmune developmentInfectionPreterm infant

Identifiers

PMID38775927
PMCPMC11621174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.